Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Biosimilars Program Gets Seed Money In Administration's FY '11 Budget

Executive Summary

FDA plans to spend $5.7 million in fiscal 2011 to develop drug review standards and make other preparations for an approval pathway for follow-on biologics

You may also be interested in...



FDA Funding Bill In Senate Gives Generic Drugs More, But Commissioner Less

A Senate Appropriations Committee-approved funding package would provide the Center for Drug Evaluation and Research with $5 million more than requested by the Obama administration

FDA Funding Bill In Senate Gives Generic Drugs More, But Commissioner Less

A Senate Appropriations Committee-approved funding package would provide the Center for Drug Evaluation and Research with $5 million more than requested by the Obama administration

Generic User Fees "Very High Priority" For FDA

Commissioner Hamburg is "optimistic" that industry and the agency can reach an agreement.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051904

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel